EBITDA Margin % is calculated as EBITDA divided by its Revenue. Creo Medical Group's EBITDA for the
six
months ended in Dec. 2025 was €-37.61 Mil. Creo Medical Group's Revenue for the
six
months ended in Dec. 2025 was €4.34 Mil. Therefore, Creo Medical Group's EBITDA margin for the quarter that ended in Dec. 2025 was -865.86%.
Creo Medical Group (FRA:1RC) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Creo Medical Group EBITDA Margin % Related Terms
Creo Medical Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1RC vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Creo Medical Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creo Medical Group EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Creo Medical Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Creo Medical Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creo Medical Group (FRA:1RC) has a EBITDA Margin % of -865.86% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Creo Medical Group and its competitors. According to the industry distribution chart, Creo Medical Group ranks #727 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 89.1%.
Is Creo Medical Group's EBITDA Margin % too high?
Creo Medical Group's current EBITDA Margin % is -865.86%. Based on the distribution chart, Creo Medical Group ranks #727 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Creo Medical Group has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #727 out of 816 companies for EBITDA Margin %. This places Creo Medical Group in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Creo Medical Group and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current EBITDA Margin % is -865.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (FRA:1RC) has a current EBITDA Margin % of -865.86%. The stock's GF Value™ is €0.18, compared to a current price of €0.15 — trading 18.9% below its estimated fair value. The current EBITDA Margin % is -865.86%. Creo Medical Group's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Creo Medical Group (FRA:1RC), the current EBITDA Margin % is -865.86% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (FRA:1RC) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of €0.15 is trading 18.9% below its estimated GF Value™ of €0.18.
Key valuation signals for FRA:1RC:
EBITDA Margin %: -865.86%
GF Value™: €0.18 vs. price of €0.15 (18.9% below fair value)
No single metric tells the full story. See the FRA:1RC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
53GF Score
Get the complete analysis for FRA:1RC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1RC has been successfully added to your 
